AstraZeneca licenses out Crohn's antibody for US$250mln
AstraZeneca PLCs LONAZN biologics research and development arm MedImmune has entered into a licensing agreement with Allergan PLC for the global rights to synthetic antibody MEDI2070.MEDI2070 is...
View ArticleAstraZeneca agrees $250 million licensing agreement with Allergan
Allergan has entered into a licensing agreement with MedImmune of AstraZeneca for the global rights of MedI2070 a synthetic antibody. MEDI2070 is presently going through Phase IIb clinical trials for...
View ArticleEisai Inc. and Arena Pharmaceuticals Announce Availability of OnceDaily...
WOODCLIFF LAKE N.J. and SAN DIEGO Oct. 3 2016 PRNewswire &160;Eisai Inc. and Arena Pharmaceuticals Inc. NASDAQ ARNA today announced the availability of BELVIQ XR&174; lorcaserin HCl CIV...
View ArticleAstraZeneca i nytt avtal med Allergan
Medimmune utlicensierar utvecklingen av en lkemedelskandidat mot Crohns sjukdom och ulcers kolit.
View ArticleAstraZeneca Inks Upto$1.5B Licensing Deal With Allergan for MEDI270
Allergan said today it has acquired global rights to AstraZeneca’s midstage inflammatory disorder candidate MEDI2070 through a licensing deal that could generate up to $1.52 billionplus for...
View ArticleAZ sells potential Crohn's drug to Allergan
AstraZeneca is continuing its strategy of outlicensing drugs outside its core areas selling offÂa midstage pipeline CrohnÂs disease drug to Allergan in a deal potentially worth more than $1.5...
View ArticleAllergan Enters $1.5 Billion Licensing Agreement with AstraZeneca for...
DUBLIN Oct. 3 2016 PRNewswire &8212; Allergan plc NYSE AGN today announced that it has entered into a licensing agreement with MedImmune AstraZeneca&8217;s global biologics research and...
View ArticleAstraZeneca Inks Upto$1.5B Licensing Deal With Allergan for MEDI2070
Allergan said today it has acquired global rights to AstraZeneca’s midstage inflammatory disorder candidate MEDI2070 through a licensing deal that could generate up to $1.52 billionplus for...
View ArticleGut Fungus Suspected in Crohn's Disease
Fungi like bacteria are present in everyone’s intestines Read more on ScientificAmerican.com
View ArticleAZ grants Allergan rights to antiIL23 mAb
The MedImmune LLC unit of AstraZeneca plc LSEAZN; NYSEAZN granted Allergan plc NYSEAGN exclusive worldwide rights to MEDI2070 a human mAb against interleukin23 IL23. The candidate is in a Phase IIb...
View ArticleCimzia passes Phase III psoriasis test
UCB Group EuronextUCB and Dermira Inc. NASDAQDERM said both doses of Cimzia certolizumab pegol met the coprimary endpoints of the Phase III CIMPASI2 study to treat moderate to severe chronic plaque...
View ArticleAsana Medical Inc.'s Preclinical Study Indicates Promising Solution to Treat...
MIAMI LAKES FL Marketwired 100416 Asana Medical Inc. "Asana" the "Company" a regenerative medicine company focused on development and commercialization of its innovative ExtraCellular Matrix Hydrogel...
View ArticlePharmas Nutritional Value
With previous senior management roles at both Novartis and Boehringer Ingelheim Greg Behar is a pharma man or he was. In 2014 he became CEO of Nestl Health Science a company whose mission is to place...
View Article2 mgkgday azathioprine best for Crohn's in Chinese patients
HealthDayFor Chinese patients with Crohn's disease CD 2 mgkgday azathioprine AZA seems more effective than 1 mgkgday according to a study published online Sept. 21 in the Journal of Digestive Diseases.
View ArticleAllergan picks up AZ Crohns drug in $1.52bn deal
AstraZeneca's biologics research and development arm MedImmune has signed over global rights to its experimental Crohn's disease drug MEDI2070 to Allergan in a deal potentially worth $1.52 billion.
View ArticleAllergan Gains Licensing Rights to AstraZeneca's Inflammatory Disease Candidate
NewsMEDI2070 is in development as a nextgeneration IL23only targeted therapy for Crohn's disease and ulcerative colitis.
View ArticleAllergan enters billiondollar deal for MedImmune's Crohn'scolitis candidate
AZ's MedImmune LLC granted Allergan PLC exclusive global rights to develop and sell its MEDI2070 an interleukin23 monoclonal antibody in Phase IIb for Crohn's disease and entering Phase II ulcerative...
View ArticleResearch aims to improve treatment for chronic bowel conditions
In Canada one in every 150 people has inflammatory bowel disease IBD. There are more than 10000 new diagnoses of IBD each year and the number of Canadian children diagnosed with Crohn's disease has...
View ArticleRedHill Biopharma Announces Initiation of Phase II Study with YELIVA in...
The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVA ABC294640 in patients with advanced hepatocellular carcinoma HCC the most common primary malignant cancer of the...
View ArticleRedHill Biopharma Announces Initiation of Phase II Study with YELIVATM in...
The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVATMÂABC294640 in patients with advanced hepatocellular carcinoma HCC the most common primary malignant cancer of the...
View Article